ERVW-1 and infection: Weeks 28 (4 weeks following the first Ad26 prime), 40 (4 weeks following the second Ad26 dose), 50 (2 weeks following the first MVA/Env subunit boost) and 62 (2 weeks following the second MVA/Env subunit boost) post-infection were selected for analysis.